System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 1 citation

PubMed: 38161985 DOI: 10.1016/j.jvacx.2023.100412

Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities.

Vaccine X 15:100412

Authors: Asae Suita, Satoko Ohfuji, Ayane Kasamatsu, Kyoko Kondo, Hiroyuki Nakata, Tetsuya Kita, Akifumi Deguchi, Mikio Fujimoto, Kazuko Iba, Hideki Sakamoto, Kaori Iwasaka, Noboru Sakamoto, Hikaru Sakamoto, Yoshiko Yodoi, Yasutoshi Kido, Yu Nakagama, Ayako Konishi, Emiko Mukai, Kazuhiro Matsumoto, Tomoka Matsuura, Tetsuo Kase, Hiroshi Kakeya, Wakaba Fukushima, Yoshio Hirota

Affiliations

  • Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka-city, Osaka 545-8585, Japan.
  • Research Center for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka-city, Osaka 545-8585, Japan.
  • Management Bureau, Osaka Metropolitan University Hospital, 1-5-7, Asahi-machi, Abeno-ku, Osaka-city, Osaka 545-8586, Japan.
  • Keai Long-Term Care Health Facility for the Elderly, 112, Hara, Takatsuki-city, Osaka 569-1051, Japan.
  • Yuai Long-Term Care Health Facility for the Elderly, 2-2-58, Tsukuda, Nishiyodogawa-ku, Osaka-city, Osaka 555-0001, Japan.
  • Kouseien Long-Term Care Health Facility for the Elderly, 3-1-16, Imafuku-Nishi, Joto-ku, Osaka-city, Osaka 536-0004, Japan.
  • Tamagushi-sumire-en Long-Term Care Health Facility for the Elderly, 3-2-3, Tamagushicho-Nishi, HigashiOsaka-city, Osaka 578-0934, Japan.
  • Tsukumo Long-Term Care Health Facility for the Elderly, 4-7-2, Tsukumodai, Suita-city, Osaka 565-0862, Japan.
  • Sayamanosato Long-Term Care Health Facility for the Elderly, 2-185-11, Iwamuro, Osakasayama city 589-0032, Japan.
  • Sakuragawa Long-Term Care Health Facility for the Elderly, 4-10-13, Sakuragawa, Naniwa-ku, Osaka-city, Osaka 556-0022, Japan.
  • Yukyuen Long-Term Care Health Facility for the Elderly, 5-1, Yamatake, Yao-city, Osaka 581-0864, Japan.
  • Kuwanomi Long-Term Care Health Facility for the Elderly, 4-4-5, Kuwadu, Higashisumiyoshi-ku, Osaka-city, Osaka 546-0041, Japan.
  • Department of Parasitology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka-city, Osaka 545-8585, Japan.
  • Department of Clinical Infection Control, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka-city, Osaka 545-8585, Japan.
  • Clinical Epidemiology Research Center, Medical Co. LTA (SOUSEIKAI), 3-6-1, Kashii-Teriha, Higashi-ku, Fukuoka-city, Fukuoka 813-0017, Japan.

Abstract

Background

To evaluate antibody responses against the primary series of vaccination of severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2] vaccines in the staff and residents of Japanese geriatric intermediate care facilities.

Methods

All subjects (159 staff and 96 residents) received two doses of the BNT162b2 mRNA vaccine 3 weeks apart. Baseline data of subject were collected using a structured form. Serum samples were collected three times: before vaccination, 3 weeks after the first dose, and 4 weeks after the second dose, and anti-receptor binding domain of the spike protein of SARS-CoV-2 [anti-RBD] IgG was measured using two immunoassays.

Results

After the second dose, geometric mean titers [GMT] of anti-RBD with both the Abbott and Roche assay were significantly lower in residents than staff (2282 AU/mL vs. 8505 AU/mL, and 258 U/mL vs. 948 U/mL, respectively). Multivariate analysis of characteristics affecting antibody responses (≥1280 AU/mL for Abbott and > 210 U/mL for Roche) showed lower odds ratios [ORs] for older age (adjusted OR per 10 year increase [aOR] = 0.62, 95 % confidence interval [95 %CI]; 0.38-1.02), steroid usage (aOR = 0.09, 95 %CI; 0.01-0.60) and regular nonsteroidal anti-inflammatory drugs [NSAIDs] usage (aOR = 0.16, 95 %CI; 0.03-0.88).

Conclusions

Elderly people and steroid and NSAID users had lower antibody responses following the second vaccine dose.

MeSH

Antibody Formation, Sars-Cov-2, Vaccines, Anti-Inflammatory Agents, Non-Steroidal, Vaccination, Intermediate Care Facilities, Steroids

Cited by